Treatment of Glioblastoma: Current Challenges and Future Prospects
Deadline for manuscript submissions: 30 June 2024 | Viewed by 76
Glioblastoma (GBM) is the most common primary malignant brain tumor. The current standard of care treatment for GBM includes maximal safe surgical resection with neuromonitoring followed by concurrent chemoradiation therapy and maintenance chemotherapy with temozolomide. Recently, novel therapeutic approaches such as immunotherapy and electric field therapy have been introduced.
Once tumors progress after first-line therapy, treatment options are limited and the management of recurrent glioblastoma remains challenging. In recent years, new treatments have been tested on recurrent glioblastoma patients. These include immunotherapy, antiangiogenic treatment, targeted therapy and combination regimens.
Local therapy with re-surgery or re-irradiation and traditional systemic therapy with nitrosoureas and temozolomide showed limited efficacy. In particular, molecular targeted therapy could show efficacy in selected patients with specific gene mutations.
This Special Issue, “Treatment of Glioblastoma: Current Challenges and Future Prospects”, is aiming to collect original articles and reviews related to diagnostic, therapeutic and experimental models in primary and recurrent GBM.
Prof. Dr. Marco Stein
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- electric field therapy